×
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13

SI-BONE Stock Forecast, Price & News

$13.60
+0.40 (+3.03%)
(As of 07/1/2022 03:59 PM ET)
Add
Compare
Today's Range
$13.03
$13.64
50-Day Range
$12.05
$20.54
52-Week Range
$11.89
$32.13
Volume
4,614 shs
Average Volume
282,625 shs
Market Capitalization
$460.82 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$31.57

SI-BONE MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
132.1% Upside
$31.57 Price Target
Short Interest
Bearish
6.41% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.44
Upright™ Environmental Score
News Sentiment
N/A
Insider Trading
Selling Shares
$369,455 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($1.93) to ($1.72) Per Share

Overall MarketRank

MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.

2.21 out of 5 stars

Medical Sector

275th out of 1,428 stocks

Surgical & Medical Instruments Industry

30th out of 138 stocks

30 days | 90 days | 365 days | Advanced Chart

Receive SIBN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for SI-BONE and its competitors with MarketBeat's FREE daily newsletter.

SI-BONE logo

About SI-BONE (NASDAQ:SIBN) Stock

SI-BONE, Inc., a medical device company, develops implantable devices used to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers iFuse, a minimally invasive surgical implant system to address sacroiliac joint dysfunction and degeneration, adult deformity, and pelvic ring traumatic fractures. The company also provides iFuse-3D, a titanium implant that combines the triangular cross-section of the iFuse implant with the proprietary 3D-printed porous surface and fenestrated design; and iFuse-TORQ, a set of 3D-printed threaded implants designed to treat fractures of the pelvis and for minimally invasive sacroiliac joint fusion. It markets its products primarily with a direct sales force, as well as through distributors. The company was incorporated in 2008 and is headquartered in Santa Clara, California.

SIBN Stock News Headlines

Former Lawyer Went From $50K To $5.3M Trading Options
Slaving away for 70 hrs a week as a lawyer in Chicago, I was miserable. I ran into guys who worked the trading floor at the local exchange. I began trading the same way they did. I started out with $50K (much more than I needed, actually). I grew my $50K into $5.3M
Aurora Spine Has Three Shots On Goal
Former Lawyer Went From $50K To $5.3M Trading Options
Slaving away for 70 hrs a week as a lawyer in Chicago, I was miserable. I ran into guys who worked the trading floor at the local exchange. I began trading the same way they did. I started out with $50K (much more than I needed, actually). I grew my $50K into $5.3M
SI-BONE: Q4 Earnings Insights
SI-BONE guides Q4 and FY21 revenue above consensus
Is SI-BONE, Inc. (SIBN) Going to Burn These Hedge Funds?
See More Headlines

Industry, Sector and Symbol

Industry
Surgical & medical instruments
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:SIBN
Fax
N/A
Employees
352
Year Founded
N/A

Company Calendar

Last Earnings
5/09/2022
Today
7/04/2022
Next Earnings (Estimated)
8/01/2022
Fiscal Year End
12/31/2022

Price Target and Rating

Average Stock Price Forecast
$31.57
High Stock Price Forecast
$36.00
Low Stock Price Forecast
$25.00
Forecasted Upside/Downside
+132.1%
Consensus Rating
Buy
Rating Score (0-4)
3
Research Coverage
6 Analysts

Profitability

Net Income
$-56,570,000.00
Pretax Margin
-67.00%

Debt

Sales & Book Value

Annual Sales
$90.15 million
Book Value
$4.01 per share

Miscellaneous

Free Float
32,054,000
Market Cap
$460.82 million
Optionable
Not Optionable
Beta
1.41














SI-BONE Frequently Asked Questions

Should I buy or sell SI-BONE stock right now?

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for SI-BONE in the last twelve months. There are currently 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" SI-BONE stock.
View analyst ratings for SI-BONE
or view top-rated stocks.

What is SI-BONE's stock price forecast for 2022?

6 brokerages have issued 12-month price targets for SI-BONE's stock. Their SIBN stock forecasts range from $25.00 to $36.00. On average, they anticipate SI-BONE's share price to reach $31.57 in the next year. This suggests a possible upside of 132.1% from the stock's current price.
View analysts' price targets for SI-BONE
or view top-rated stocks among Wall Street analysts.

How has SI-BONE's stock performed in 2022?

SI-BONE's stock was trading at $22.21 at the beginning of the year. Since then, SIBN shares have decreased by 38.8% and is now trading at $13.60.
View the best growth stocks for 2022 here
.

When is SI-BONE's next earnings date?

SI-BONE is scheduled to release its next quarterly earnings announcement on Monday, August 1st 2022.
View our earnings forecast for SI-BONE
.

How were SI-BONE's earnings last quarter?

SI-BONE, Inc. (NASDAQ:SIBN) posted its quarterly earnings data on Monday, May, 9th. The company reported ($0.52) EPS for the quarter, missing analysts' consensus estimates of ($0.43) by $0.09. The company earned $22.44 million during the quarter, compared to the consensus estimate of $22.37 million. SI-BONE had a negative trailing twelve-month return on equity of 44.52% and a negative net margin of 67.00%. During the same quarter in the previous year, the company earned ($0.37) EPS.
View SI-BONE's earnings history
.

What guidance has SI-BONE issued on next quarter's earnings?

SI-BONE issued an update on its FY 2022 earnings guidance on Monday, June, 6th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $106.00 million-$108.00 million, compared to the consensus revenue estimate of $107.35 million.

Who are SI-BONE's key executives?

SI-BONE's management team includes the following people:
  • Ms. Laura A. Francis MBA, CEO & Director (Age 55, Pay $879.74k) (LinkedIn Profile)
  • Mr. Anshul Maheshwari, Chief Financial Officer (Age 44, Pay $511.05k)
  • Mr. Anthony J. Recupero, Pres of Commercial Operations (Age 63, Pay $665.91k) (LinkedIn Profile)
  • Mr. Michael A. Pisetsky, Sr. VP of Operations & Admin., Sec. and Chief Legal Officer (Age 44) (LinkedIn Profile)
  • Dr. Scott A. Yerby, Sr. VP of Engineering & CTO (Age 54)
  • Mr. Joseph W. Powers, VP of Corp. Marketing (Age 62)
  • Dr. Daniel Joseph Cher, Sr. VP of Clinical & Regulatory Affairs (Age 57)
  • Dr. W. Carlton Reckling, Chief Medical Officer & VP of Medical Affairs (Age 60)
  • Mr. Nikolas F. Kerr, Sr. VP of Product, Strategy & Bus. Devel. (Age 50)
  • Ms. Joyce Goto, VP & Corp. Controller (Age 48)

What is Jeffrey Dunn's approval rating as SI-BONE's CEO?

10 employees have rated SI-BONE CEO Jeffrey Dunn on Glassdoor.com. Jeffrey Dunn has an approval rating of 41% among SI-BONE's employees. This puts Jeffrey Dunn in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of SI-BONE own?

Based on aggregate information from My MarketBeat watchlists, some companies that other SI-BONE investors own include (HON), CVS Health (CVS), Home Depot (HD), Procter & Gamble (PG), Raytheon Technologies (RTX), Thermo Fisher Scientific (TMO), Verizon Communications (VZ), Alibaba Group (BABA), Cisco Systems (CSCO) and CSX (CSX).

When did SI-BONE IPO?

(SIBN) raised $84 million in an initial public offering on Wednesday, October 17th 2018. The company issued 6,000,000 shares at $13.00-$15.00 per share. Morgan Stanley and BofA Merrill Lynch acted as the underwriters for the IPO and Canaccord Genuity and JMP Securities were co-managers.

What is SI-BONE's stock symbol?

SI-BONE trades on the NASDAQ under the ticker symbol "SIBN."

How do I buy shares of SI-BONE?

Shares of SIBN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is SI-BONE's stock price today?

One share of SIBN stock can currently be purchased for approximately $13.60.

How much money does SI-BONE make?

SI-BONE (NASDAQ:SIBN) has a market capitalization of $460.82 million and generates $90.15 million in revenue each year. The company earns $-56,570,000.00 in net income (profit) each year or ($1.85) on an earnings per share basis.

How many employees does SI-BONE have?

SI-BONE employs 352 workers across the globe.

How can I contact SI-BONE?

SI-BONE's mailing address is 471 EL CAMINO REAL SUITE 101, SANTA CLARA CA, 95050. The official website for SI-BONE is www.si-bone.com. The company can be reached via phone at (408) 207-0700 or via email at investors@si-bone.com.

This page (NASDAQ:SIBN) was last updated on 7/4/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.